Prothena Corp. plc (PRTA), a late-stage clinical biotechnology company, has multiple data readouts scheduled for the coming quarters across four clinical programs.
The company's pipeline comprises of therapeutic candidates for a number of neurodegenerative and rare peripheral amyloid diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com